<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="28318">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01769716</url>
  </required_header>
  <id_info>
    <org_study_id>UCBGDD</org_study_id>
    <nct_id>NCT01769716</nct_id>
  </id_info>
  <brief_title>Umbilical Cord Blood Therapy for Global Developmental Delay</brief_title>
  <official_title>Umbilical Cord Blood Therapy for Children With Global Developmental Delay</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MinYoung Kim, M.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CHA University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Bundang CHA Hospital</source>
  <oversight_info>
    <authority>Korea: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This open-label study aims to evaluate the safety and efficacy of autologous or allogeneic
      umbilical cord blood therapy for children with global developmental delay.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Global developmental delay is defined as significant delay in two or more of the following
      developmental domains: gross/fine motor, speech/language, cognition, social/personal, and
      activities of daily living.

      Umbilical cord blood has been used for inherited metabolic diseases that feature global
      developmental delay and many experimental animal studies have revealed umbilical cord blood
      is useful to repair neurological impairments in brain.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Changes in Cognition</measure>
    <time_frame>Baseline - 6 months - 12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Korean Wechsler Preschool and Primary Scale of Intelligence (K-WPPSI) (Higher value means better cognitive function (K-WPPSI: below 70 - worst, over 130 - best)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in Cognitive Neurodevelopmental Outcome</measure>
    <time_frame>Baseline - 1 month - 3 months - 6 months - 12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Korean version of Bayley Scale of Infant Development-II Mental Scales (Higher value means better cognitive function: raw score 0 - worst, 178 - best.)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in Motor Performance</measure>
    <time_frame>Baseline - 1 month - 3 months - 6 months - 12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>GMPM (Gross Motor Performance Measure) as a standardized measurement tool for assessing quality of movement regarding 3 properties of 5 ones; alignment, coordination, dissociated movement, stability, and weight shift (range: 0~100, Higher value means better motor quality.)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Standardized Gross Motor Function</measure>
    <time_frame>Baseline - 1 month - 3 months - 6 months - 12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>GMFM (Gross Motor Function Measure) as a standardized measurement tool for assessing Gross Motor Function consisting of sub-scales; lying &amp; rolling, sitting, crawling &amp; kneeling, standing, walking, running &amp; jumping (range: 0~100 , Higher value means better gross motor function.)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Motor Neurodevelopmental Outcome</measure>
    <time_frame>Baseline - 1 month - 3 months - 6 months - 12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Korean version of Bayley Scale of Infant Development-II Motor Scales (Higher value means better motor function: raw score 0 - worst, 112 - best)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Functional Independence in Daily Activities</measure>
    <time_frame>Baseline - 1 month - 3 months - 6 months - 12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>WeeFIM (Functional Independence Measure for Children) measures functional independence in daily activities. WeeFIM contains 18 items and each item is ranked from complete dependence (scored as 1) to complete independence (scored as 7). The range is from 18 to 126 and higher scores mean more independent performance in daily activities.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Visual Perception Test</measure>
    <time_frame>Baseline - 1 month - 3 months - 6 months - 12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Visual perception function is evaluated with one of three measures: DTVP (Developmental Test of Visual Perception), MVPT (Motor-free Visual Perception Test), and VMI (Visual-Motor Integration). All can be scored as percentile rank from 0 to 100. Higher values mean better visual perception ability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Muscle Strength</measure>
    <time_frame>Baseline - 1 month - 3 months - 6 months - 12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Summation of MMT (manual muscle testing): summated scores of the manual muscle strength test (zero=0, trace=1, poor=2, fair=3, good=4, normal=5) for flexors, extensors, abductors, and adductors of bilateral shoulder and hip joints; flexors and extensors of bilateral elbow, wrist, and knee; dorsiflexors and plantar flexors of the ankles (range: 0 ~ 160). Higher scores mean better muscle strength.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Functional Performance in Daily Activities</measure>
    <time_frame>Baseline - 1 month - 3 months - 6 months - 12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Pediatric Evaluation of Disability Inventory (PEDI) for assessing functional performance in daily activities in children (All values are adjusted and higher value means better functional performance, 0 - worst, 100 - best.)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Language Evaluation</measure>
    <time_frame>Baseline - 6 months - 12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Sequenced Language Scale for Infant (SELSI), Preschool Receptive-Expressive Language Scale (PRES) or Korean Western Aphasia Battery (K-WAB)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Brain glucose metabolism</measure>
    <time_frame>Baseline - 12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>FDG-PET</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Global Developmental Delay</condition>
  <arm_group>
    <arm_group_label>Umbilical cord blood therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Allogeneic umbilical cord blood will be administered intravenously or intraarterially under non-myeloablative immunosuppression. In case of autologous umbilical cord blood, immunosuppression is not required.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Umbilical Cord Blood administration</intervention_name>
    <arm_group_label>Umbilical cord blood therapy</arm_group_label>
    <other_name>Autologous or Allogeneic Umbilical Cord Blood</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Global developmental delay

          -  Willing to comply with all study procedure

        Exclusion Criteria:

          -  Medical instability including pneumonia or renal function at enrollment

          -  Poor cooperation of guardian,including inactive attitude for rehabilitation and
             visits for follow-up

          -  Uncontrolled persistent epilepsy

          -  Not eligible according to the principal investigator
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>15 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MinYoung Kim, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHA University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>MinYoung Kim, M.D., Ph.D.</last_name>
    <phone>82-31-780-6281</phone>
    <email>kmin@cha.ac.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kyunghoon Min, M.D.</last_name>
    <phone>82-31-780-6281</phone>
    <email>minkh@chamc.co.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHA Bundang Medical Center, CHA University</name>
      <address>
        <city>Seongnam-si</city>
        <state>Gyeonggi-do</state>
        <zip>463-712</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MinYoung Kim, M.D., Ph.D.</last_name>
      <phone>82-31-780-6281</phone>
      <email>kmin@cha.ac.kr</email>
    </contact>
    <contact_backup>
      <last_name>Kyunghoon Min, M.D.</last_name>
      <phone>82-31-780-6281</phone>
      <email>minkh@chamc.co.kr</email>
    </contact_backup>
    <investigator>
      <last_name>MinYoung Kim, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Myung Seo Kang, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sang Heum Kim, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Su Jin Jang, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kyunghoon Min, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Su Jin Yoo, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 31, 2014</lastchanged_date>
  <firstreceived_date>January 15, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Bundang CHA Hospital</investigator_affiliation>
    <investigator_full_name>MinYoung Kim, M.D.</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Global developmental delay</keyword>
  <keyword>Umbilical cord blood</keyword>
  <keyword>Rehabilitation</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
